Skip to main content
ENTROPY NEURODYNAMICS LIMITED logo

ENTROPY NEURODYNAMICS LIMITED — Investor Relations & Filings

Ticker · ENP ISIN · AU0000433583 ASX Professional, scientific and technical activities
Open in API
Filings indexed 393 across all filing types
Latest filing 2022-10-24 AGM Information
Country AU Australia
Listing ASX ENP

About ENTROPY NEURODYNAMICS LIMITED

https://entropyneurodynamics.com/

Entropy Neurodynamics Limited focuses on the research and development of computational frameworks and analytical tools derived from information theory and dynamical systems. The company specializes in the study of neurodynamics, exploring the complex, non-linear interactions within neural systems and the application of entropy-based metrics to quantify brain state transitions. Its core activities include the design of algorithms for neural data processing, the modeling of cognitive architectures, and the development of technologies aimed at monitoring or modulating neural activity. By integrating principles of thermodynamics and neuroscience, the firm provides technical solutions for understanding neural information flow and optimizing the performance of both biological and synthetic neural networks.

Recent filings

Filing Released Lang Actions
2022 AGM Letter to Shareholders and Proxy 8 pages 459.7KB
AGM Information Classification · 95% confidence The document is an ASX announcement dated October 2022 related to Exopharm Limited's Annual General Meeting (AGM). It includes an AGM letter to shareholders, proxy form, details about the meeting date, location, virtual attendance instructions, business and resolutions to be voted on, and proxy voting instructions. There is no financial data or detailed financial performance information. The document is clearly related to the AGM event and materials shared with shareholders to facilitate participation and voting. This matches the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM. The document length is substantial (15,000 characters), indicating it is not a brief announcement or a report publication announcement. Therefore, the classification is AGM Information (AGM-R) with high confidence.
2022-10-24 English
2022 AGM Notice of Meeting and Proxy 78 pages 1.8MB
AGM Information Classification · 100% confidence The document is an ASX announcement dated 25 October 2022 regarding the 2022 Annual General Meeting (AGM) of Exopharm Limited. It includes the Notice of Meeting and Proxy Form for the AGM scheduled for 24 November 2022. The content includes details about the meeting venue, voting instructions, agenda items including the financial statements and reports for the year ended 30 June 2022, resolutions to be voted on, and explanatory statements. The document is clearly related to the AGM and contains the official notice and proxy materials for the meeting, not the actual annual report or financial statements themselves. Therefore, it fits the category of AGM Information (AGM-R).
2022-10-24 English
Change in substantial holding 3 pages 108.1KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 filed under the Corporations Act 2001 Section 671B, titled 'Notice of change of interests of substantial holder.' It details changes in voting power and relevant interests of a substantial shareholder, including dates, share classes, and consideration amounts. The form is regulatory in nature, reporting changes in substantial shareholdings as required by law. It does not contain financial statements, management discussion, or earnings data. It is not an announcement of a report but a regulatory filing about shareholding changes. Therefore, it fits the category of Major Shareholding Notification (MRQ).
2022-10-23 English
Upcoming Webinar 16 pages 4.3MB
Investor Presentation Classification · 95% confidence The document is an ASX announcement from Exopharm Limited dated 20 October 2022. It primarily provides information about an upcoming webinar focused on genetic medicines and drug delivery technologies, specifically exosomes. The content includes a detailed presentation-style explanation of the scientific and technological aspects of exosome-based drug delivery, advantages over lipid nanoparticles, and the therapeutic potential of genetic medicines. There are no financial statements, earnings data, regulatory certifications, or voting results. The document is informational and promotional in nature, aimed at investors and the public to inform them about the webinar and the company's technology. It is not a transcript of a call, not a financial report, not a regulatory filing, nor a notice of dividend or capital change. The document fits best as an Investor Presentation (IP) because it is a detailed presentation for investors focusing on the company's technology, strategy, and market position, even though it is in the form of an announcement for a webinar with presentation content included. The length (15,000 characters) and detailed content support this classification rather than a brief announcement or a report publication announcement.
2022-10-19 English
Notification regarding unquoted securities - EX1 7 pages 30.2KB
Share Issue/Capital Change Classification · 100% confidence The document is a notification regarding the issue of unquoted equity securities, specifically performance rights issued under an employee incentive scheme. It details the number of securities issued, the issue date, and information about key management personnel receiving these securities. The document is an announcement of a securities issuance event rather than a financial report or detailed analysis. It fits the description of a Share Issue/Capital Change announcement, which covers new share issues or capital changes. The document is not a full financial report, earnings release, or regulatory filing of another type, but a specific announcement about securities issuance.
2022-10-13 English
Upcoming Webinar 14 pages 3.1MB
Investor Presentation Classification · 95% confidence The document is an ASX announcement from Exopharm Limited dated 13 October 2022, primarily about an upcoming webinar titled 'Exosomes: Unleashing Genetic Medicine Potential'. The content includes detailed information about the webinar, company background, technology platforms, and forward-looking statements. There is no indication of financial results, audit opinions, management changes, voting results, or regulatory filings. The document is promotional and informational about an event rather than a financial report or regulatory filing. It is not a transcript of a call, nor a report publication announcement. Given the nature of the content focusing on an upcoming event and company information, the most appropriate classification is Investor Presentation (IP). The document length (15,000 characters) supports it being a detailed presentation rather than a brief announcement or notice.
2022-10-12 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.